Strategic Timing of AntiRetroviral Treatment

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atazanavir (Primary) ; Cobicistat/darunavir (Primary) ; Darunavir (Primary) ; Dolutegravir (Primary) ; Efavirenz (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Fosamprenavir (Primary) ; Lamivudine/abacavir (Primary) ; Lamivudine/zidovudine (Primary) ; Lopinavir/ritonavir (Primary) ; Raltegravir (Primary) ; Ritonavir (Primary) ; Antiretrovirals
Indications HIV infections
Focus Adverse reactions; Therapeutic Use
Acronyms START

28 Mar 2024 This trial has been completed in Portugal, according to European Clinical Trials Database.
06 Mar 2024 Results presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
04 Mar 2023 This trial has been completed in Greece, Sweden, Czech republic, Austria, according to European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com